Tilray (TLRY) Medical, a division of Tilray Brands, announced the publication of a scientific study. This new research focuses on comparing the bioavailability of different cannabinoid formulations, taking a step forward in our understanding of medical cannabis. This pilot study shows that oral administration of Tilray THC:CBD extract formulation achieved higher THC and CBD concentrations within a shorter timeframe compared to the oromucosal delivery of nabiximols. These findings may have significant implications for clinical populations using these formulations therapeutically.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLRY:
- U.S. House okays amendment on VA cannabis recommendations, Marijuana Herald says
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Tilray announces three new medical cannabis flower varieties in Italy
- Tilray Completes Debt-for-Equity Exchange Transaction
- Tilray announces 2025 summer cannabis collection